

18W

PTO/SB/21 (02-04)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

<b>TRANSMITTAL FORM</b>  (to be used for all correspondence after initial filing)	Application Number	10/809761	
	Filing Date	March 25, 2004	
	First Named Inventor	Charles R. Stewart	
	Art Unit	N/A	
	Examiner Name	Not Yet Assigned	
Total Number of Pages in This Submission	_____	Attorney Docket Number	61683-00004USPT

**ENCLOSURES (Check all that apply)**

<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment/Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Response to Missing Parts/Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____	<input type="checkbox"/> After Allowance communication to Technology Center (TC) <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): Postcard 47 References Certificate of Mailing
<div>Remarks</div>		

**SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT**

Firm or Individual name	JENKENS & GILCHRIST, A PROFESSIONAL CORPORATION Tamsen Valoir, Ph.D.
Signature	
Date	July 27, 2004

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail, in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Dated: July 27, 2004

Signature:

(Susan B. Jensen)



I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail, in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Dated: July 27, 2004

Signature:

*Susan B. Jensen*  
(Susan B. Jensen)

Docket No.: 61683-00004USPT  
(PATENT)

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Patent Application of:  
Charles R. Stewart et al.

Application No.: 10/809761

Confirmation No.: @@@

Filed: March 25, 2004

Art Unit: N/A

For: ANTIMICROBIAL PROTEINS FROM THE  
SPO1 BACTERIOPHAGE

Examiner: Not Yet Assigned

**INFORMATION DISCLOSURE STATEMENT (IDS)**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 CFR 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement is filed more than three months after the U.S. filing date, OR more than three months after the date of entry of the national stage of a PCT application, AND after the mailing date of the first Office Action on the merits, whichever occurs first, but before the mailing date of a Final Office Action or Notice of Allowance (37 CFR 1.97(c)).

A copy of each reference on the PTO/SB/08 is attached.

In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR 1.56(a) exists. In accordance with 37 CFR 1.97(h), the filing


of this Information Disclosure statement shall not be construed to be an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

It is submitted that the Information Disclosure Statement is in compliance with 37 CFR 1.98 and the Examiner is respectfully requested to consider the listed references.

The Director is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 10-0447, under Order No. 61683-00004USPT.

Dated: July 27, 2004

Respectfully submitted,

By 

Tamsen Valoir, Ph.D.

Registration No.: 41,417

JENKENS & GILCHRIST, A PROFESSIONAL  
CORPORATION

5 Houston Center


1401 McKinney, Suite 2700

Houston, Texas 77010

(713) 951-3381

(713) 951-3314 Facsimile

Attorneys For Applicant



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>Substitute for form 1449A/B/PTO</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/809761
				Filing Date	March 25, 2004
				First Named Inventor	Charles R. Stewart
				Art Unit	N/A
				Examiner Name	Not Yet Assigned
Sheet	1	of	2	Attorney Docket Number	61683-00004USPT

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if known)			
	1	20010026795A1	10/04/2001	Merril et al.	
	2	20010043924Aaa1	11/22/2001	Carlton et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>4</sup>
		Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)				

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS						
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.				T <sup>2</sup>
	3	Air E.L., et al.(2002) Nature Med. 8:179-183.				
	4	Andrade-Gordon P. et al. (1999) Proc. Natl. Acad. Sci. U.S. 96:12257-12262				
	5	Dedonder, R.A., et al. (1977) Appl. Environ. Microbiol. 33: 989-993.				
	6	Fotsch, C., et al. (2003) Bioorganic & Medicinal Chemistry Letters 13: 2337-40.				
	7	Gadek, T.R., et al. (2002) Science 295: 1086-9.				
	8	Greene, J.R., et al. (1982) J. Virol. 41: 715-20.				
	9	Greene, J.R., et al. (1984) Proc. Natl. Acad. Sci. USA 81: 7031-5.				
	10	Hendrickson W.A., et al. (1997) In Methods in Enzymology. 276: 494-522				
	11	Pedulla M.L., et al. (2003) Corrected Sequence of the Bacteriophage P22 Genome. 185: 1475-77.				
	12	Ireton, K., et al. (1993) Genes & Dev. 7: 283-94.				
	13	Kim, L., et al. (1996) Gene 181: 71-6.				
	14	Kobayashi, K., et al. (2003) Proc. Natl. Acad. Sci. USA 100: 4678-83.				
	15	Legrain, P. (2002) Nature Biotechnology 20: 128-9.				
	16	Malys, N., et al. (2002) J. Mol. Biol. 319: 289-04.				
	17	Martin L., et al. (2003) Nature Biotech. 21:71-76				
	18	Miyazaki K., et al. (2000) J. Mol. Biol. 297:1015-1026				
	19	Noirot-Gros, M.F., et al. (2002) Proc. Natl. Acad. Sci. U.S.A. 99: 8342-8347.				
	20	Ohkanda, J., et al. (2001) Bioorganic & Medicinal Chemistry Letters 11: 761-764.				
	21	Okubo, S., et al. (1972) Biken J. 15: 81-97.				
	22	Salvemini D., et al. (1999) Science 286:304-306				
	23	Salvemini, D., et al. (2002) Nature Reviews 1: 367-74.				
	24	Sayers, J.R. (1996) Meth. Enz. 275: 227-38.				
	25	Scarlato, V., and S. Gargano (1992) Gene 118: 109-113.				
	26	Scott, J.K. (2001) in "Phage Display" C.F. Barbas, et al. (eds.) Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York. pp. 4.1-4.13.				
	27	Shamoo, Y., (1995) Nature 376: 362-6.				
	28	Shamoo Y., et. al. (1997) Nat. Struc. Biol. 4:215-222				
	29	Shamoo, Y., and T.A. Steitz. (1999) Cell 99: 155-166.				
Examiner Signature					Date Considered	

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.


Substitute for form 1449A/B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/809761
				Filing Date	March 25, 2004
				First Named Inventor	Charles R. Stewart
				Art Unit	N/A
				Examiner Name	Not Yet Assigned
Sheet	2	of	2	Attorney Docket Number	61683-00004USPT

30	Spee J.H., et al. (1993) Nucleic Acids Res. 21:777-778	
31	Smith, R.A., et al. (2001) Bioorganic and Medical Chemistry Letters 11: 2951-4	
32	Stewart, C.R. (1993) in <i>Bacillus subtilis</i> and other gram-positive bacteria (A. Sonenshein, J.A. Hoch, and R. Losick, eds. American Society for Microbiology) pp. 813-829	
33	Stewart C.R., et al. (1998) Virology 246:329-340	
34	Stewart C.R. (1999) SPO1 Phage (Myoviridae), in Encyclopedia of Virology (2nd Edition, Webster, R.G., and Granoff, A., eds.) pp. 1681-1685	
35	Stewart, C.R. et al. (Aug. 8-13, 2001) In Abstracts of the Fourteenth Evergreen International Phage Biology Meeting.	
36	Tatusova, T.A. & T.L. Madden (1999) FEMS Microbiol. Lett. 174: 247-50.	
37	Tian S.S., et al. (1998) Science 281:257-259	
38	Vandeyar, M.A., and S. A. Zahler (1986) J. Bacteriol. 167: 530-4.	
39	Wanner, B.L. (1986) J. Mol. Biol. 191: 39-58.	
40	Wei P. & Stewart C.R. (1993) A cytotoxic early gene of <i>Bacillus subtilis</i> bacteriophage SPO1. J Bacteriol. 175(24):7887-900	
41	Wei P. & Stewart C.R. (1995) Genes that protect against the host-killing activity of the E3 protein of <i>Bacillus subtilis</i> bacteriophage SPO1, J. Bacteriol. 177, 2933-2937	
42	Willats, W.G.T. (2002) Plant Molecular Biology 50: 837-54.	
43	Wrighton, N., and D. Gearing (1999) Nature Biotech. 17: 1157-8.	
44	Duckworth, D. et al, "Bacteriophages: potential treatment for bacterial infections", BioDrugs 2002;16(1):57-62	
45	Cudic, M. et al., "Intracellular targets of antibacterial peptides", Curr Drug Targets 2002 Apr;3(2):101-6.	
46	Sadler, K. et al., "Translocating proline-rich peptides from the antimicrobial peptide bacterenecin 7", Biochemistry 2002 Dec 3;41(48):14150-7.	
47	Kutter E., "Phage Therapy: Bacteriophages as Antibiotics" <a href="http://www.evergreen.edu/phage/phagetherapy.html">http://www.evergreen.edu/phage/phagetherapy.html</a> , page 1-24	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--



Application No. (if known): 10/809761

Attorney Docket No.: 61683-00004USPT

## Certificate of Mailing Under 37 CFR 1.8

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to:

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

on 7/27/04  
Date

Susan B. Jensen  
Signature

Susan B. Jensen

Typed or printed name of person signing Certificate

Note: Each paper must have its own certificate of mailing, or this certificate must identify each submitted paper.

IDS Citation  
Information Disclosure Statement  
Transmittal Letter  
47 References  
Postcard  
Certificate of Mailing